38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L

Brigatinib, an ALK tyrosine kinase inhibitor (TKI), showed superior clinical efficacy in 1L for ALK+ NSCLC compared to crizotinib in the phase III ALTA-1L trial. There is a lack of data on real-world treatment patterns and outcomes post-1L brigatinib.